Olanzapine Dosing for Children
The appropriate olanzapine dose for children depends on the indication, age, and weight, with FDA-approved starting doses of 2.5-5 mg once daily for adolescents (13-17 years) with schizophrenia or bipolar disorder, targeting 10 mg/day. 1
FDA-Approved Pediatric Dosing
Adolescents (13-17 years)
For schizophrenia:
- Starting dose: 2.5-5 mg once daily
- Target dose: 10 mg/day within several days
- Can be given without regard to meals 1
For bipolar I disorder (manic or mixed episodes):
- Starting dose: 2.5-5 mg once daily
- Target dose: 10 mg/day
- Monotherapy dosing 1
For depressive episodes associated with bipolar I disorder (in combination with fluoxetine):
- Starting dose: 2.5 mg olanzapine + 20 mg fluoxetine once daily in the evening
- Dosage adjustments made according to efficacy and tolerability
- Maximum studied: 12 mg olanzapine + 50 mg fluoxetine in children/adolescents ages 10-17 1
Children Under 13 Years
Olanzapine is NOT FDA-approved for children under 13 years of age. The FDA label specifically addresses only adolescents 13-17 years for schizophrenia and bipolar disorder 1. However, research data exists for off-label use in younger children.
Weight-Based Dosing Considerations
Lower starting doses (2.5 mg) should be considered for:
- Debilitated patients
- Patients predisposed to hypotensive reactions
- Pharmacodynamically sensitive patients
- Patients with potential for slowed metabolism 1
Research in younger children (ages 6-16) with pervasive developmental disorders used doses ranging from 2.5-20 mg/day, with a final mean dose of 10.7 mg/day 2. A population pharmacokinetic study suggests weight-normalized dosing for children ≤6 months postnatal age or <15 kg, and fixed doses for children ≥15 kg 3.
Clinical Pharmacokinetics in Children
Pharmacokinetic studies demonstrate that olanzapine concentrations in pediatric patients (ages 10-18) are comparable to nonsmoking adults but may be twice those of adult smokers 4. The mean oral clearance is 9.6 ± 2.4 L/hr with an elimination half-life of 37.2 ± 5.1 hours in young patients 4. This supports once-daily dosing starting at 5-10 mg for most adolescent patients 4.
Critical Safety Considerations
Metabolic Monitoring is Essential
Weight gain is the most prominent adverse reaction in children and adolescents, occurring more frequently than in adults and more than with risperidone or haloperidol 5, 6. The FDA label emphasizes:
- Regular weight monitoring is required
- Fasting blood glucose testing at baseline and periodically during treatment
- Fasting lipid testing at baseline and periodically during treatment
- The increased potential for weight gain and dyslipidemia in adolescents compared with adults may lead clinicians to consider other drugs first 1
Other Important Adverse Effects
- Sedation: May affect up to 50% of patients, even at study end 6
- Extrapyramidal symptoms: Mild to moderate, less than haloperidol but may be more frequent than in adults 6
- Liver enzyme elevations: Monitor ALT/AST 7
- Prolactin elevation: Less than risperidone/haloperidol 6
Practical Dosing Algorithm
For adolescents 13-17 years:
- Start: 2.5-5 mg once daily (evening preferred if sedation occurs)
- Titrate: Increase to target of 10 mg/day within several days based on tolerability
- Adjust: Can increase in 2.5-5 mg increments if needed for efficacy
- Maximum: Generally 20 mg/day (though doses up to 20 mg studied in research) 1, 6
For children under 13 years (off-label):
Research suggests starting at 2.5 mg once daily with slow titration based on weight and response, though this is not FDA-approved 3, 2. Consultation with pediatric psychiatry is strongly recommended.
Common Pitfalls to Avoid
- Do not overlook metabolic monitoring: Baseline and ongoing assessment of weight, glucose, and lipids is mandatory, not optional
- Do not use adult dosing in younger/smaller children: Pharmacokinetics differ, and weight-based adjustments may be needed for children <15 kg 3
- Do not ignore sedation: Consider evening dosing if daytime sedation occurs
- Do not combine with certain medications: Physical incompatibility exists with diazepam and lorazepam for IM formulations; avoid combining with drugs that lower seizure threshold 1
The evidence base for olanzapine in children remains limited compared to adults, with most pediatric data from open-label studies and case reports rather than large randomized controlled trials 6. Medication therapy for pediatric patients should only be undertaken after thorough diagnostic evaluation and careful consideration of potential risks 1.